SG10202104259RA - Steroids and protein-conjugates thereof - Google Patents

Steroids and protein-conjugates thereof

Info

Publication number
SG10202104259RA
SG10202104259RA SG10202104259RA SG10202104259RA SG10202104259RA SG 10202104259R A SG10202104259R A SG 10202104259RA SG 10202104259R A SG10202104259R A SG 10202104259RA SG 10202104259R A SG10202104259R A SG 10202104259RA SG 10202104259R A SG10202104259R A SG 10202104259RA
Authority
SG
Singapore
Prior art keywords
steroids
conjugates
protein
Prior art date
Application number
SG10202104259RA
Inventor
Amy Han
William Olson
J Andrew Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60409441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10202104259R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG10202104259RA publication Critical patent/SG10202104259RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
SG10202104259RA 2016-11-08 2017-11-07 Steroids and protein-conjugates thereof SG10202104259RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662419365P 2016-11-08 2016-11-08
US201762508317P 2017-05-18 2017-05-18

Publications (1)

Publication Number Publication Date
SG10202104259RA true SG10202104259RA (en) 2021-06-29

Family

ID=60409441

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10202104259RA SG10202104259RA (en) 2016-11-08 2017-11-07 Steroids and protein-conjugates thereof

Country Status (16)

Country Link
US (4) US10711032B2 (en)
EP (1) EP3538539A2 (en)
JP (2) JP7330101B2 (en)
KR (2) KR20240025695A (en)
CN (2) CN110291097A (en)
AU (1) AU2017359043B2 (en)
BR (1) BR112019009019A2 (en)
CA (1) CA3042428A1 (en)
CL (1) CL2019001259A1 (en)
CO (1) CO2019005966A2 (en)
IL (2) IL307357A (en)
MX (2) MX2019005330A (en)
PH (1) PH12019501021A1 (en)
SG (1) SG10202104259RA (en)
WO (1) WO2018089373A2 (en)
ZA (1) ZA201902871B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745748C2 (en) 2016-06-02 2021-03-31 Эббви Инк. Agonist of the glucocorticoid receptor and its immunoconjugates
JP7330101B2 (en) 2016-11-08 2023-08-21 レゲネロン ファーマシューティカルス，インコーポレーテッド Steroids and their protein conjugates
EP3624894A1 (en) 2017-05-18 2020-03-25 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
KR20200085807A (en) 2017-11-07 2020-07-15 리제너론 파마슈티칼스 인코포레이티드 Hydrophilic linker for antibody drug conjugates
PT3658192T (en) 2017-12-01 2021-06-25 Abbvie Inc Glucocorticoid receptor agonist and immunoconjugates thereof
JP7366028B2 (en) * 2018-01-08 2023-10-20 レゲネロン ファーマシューティカルス，インコーポレーテッド Steroids and their antibody conjugates
JP2021523147A (en) 2018-05-09 2021-09-02 レゲネロン ファーマシューティカルス，インコーポレーテッド Anti-MSR1 antibody and how to use it
CA3149482A1 (en) 2019-08-02 2021-02-11 Mersana Therapeutics, Inc. Bis-[n-((5-carbamoyl)-1h-benzo[d]imidazol-2-yl)-pyrazol-5-carboxamide] derivatives and related compounds as sting (stimulator of interferon genes) agonists for the treatment of cancer
JP2023515941A (en) 2020-02-28 2023-04-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Bispecific antigen-binding molecules that bind to HER2 and methods of using the same
IL299153A (en) 2020-07-13 2023-02-01 Regeneron Pharma Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
IL301702A (en) 2020-10-22 2023-05-01 Regeneron Pharma Anti-fgfr2 antibodies and methods of use thereof
EP4243876A1 (en) 2020-11-10 2023-09-20 Regeneron Pharmaceuticals, Inc. Selenium antibody conjugates
WO2022120132A1 (en) * 2020-12-04 2022-06-09 Dyne Therapeutics, Inc. Antibody-oligonucleotide complexes and uses thereof
WO2022135332A1 (en) * 2020-12-21 2022-06-30 映恩生物制药（苏州）有限公司 Steroid conjugate
EP4289857A1 (en) * 2021-02-04 2023-12-13 Shanghai Senhui Medicine Co., Ltd. Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine
WO2022171101A1 (en) * 2021-02-10 2022-08-18 映恩生物制药（苏州）有限公司 Steroid conjugate
TW202304462A (en) 2021-03-23 2023-02-01 美商美國禮來大藥廠 Glucocorticoid receptor agonists
AR125084A1 (en) 2021-03-23 2023-06-07 Lilly Co Eli NOVEL GLUCOCORTICOID RECEPTOR AGONISTS
AR125079A1 (en) 2021-03-23 2023-06-07 Lilly Co Eli CARBOXY-SUBSTITUTED GLUCOCORTICOID RECEPTOR AGONISTS
CN113264983A (en) * 2021-05-20 2021-08-17 联宁（苏州）生物制药有限公司 Synthetic method of linker LND1088 for antibody-conjugated drug
WO2023025248A1 (en) * 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 Steroid compound and conjugate thereof
CN114394933B (en) * 2022-01-07 2023-08-22 厦门沃克沃德医药科技有限公司 Synthesis method of 11, 12-dihydro-gamma-oxo-dibenzo [ F ] azo-5- (6H) -butyric acid
WO2023137026A1 (en) 2022-01-12 2023-07-20 Regeneron Pharmaceuticals, Inc. Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
US20240067640A1 (en) 2022-03-11 2024-02-29 Firefly Bio, Inc. Phenyl maleimide linker agents
US20240082414A1 (en) 2022-05-13 2024-03-14 Eli Lilly And Company Human tumor necrosis factor alpha antibody glucocorticoid conjugates
TW202400266A (en) * 2022-05-18 2024-01-01 大陸商成都百利多特生物藥業有限責任公司 Ligand-drug conjugate and use thereof
WO2023235738A1 (en) 2022-06-02 2023-12-07 Eli Lilly And Company Human interleukin-4 receptor alpha antibody glucocorticoid conjugates
WO2023250341A2 (en) 2022-06-22 2023-12-28 Eli Lilly And Company Human cd33 antibodies and glucocorticoid conjugates
WO2024020164A2 (en) 2022-07-21 2024-01-25 Firefly Bio, Inc. Glucocorticoid receptor agonists and conjugates thereof
WO2024064779A1 (en) 2022-09-22 2024-03-28 Eli Lilly And Company Glucocorticoid receptor agonists

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2737518A (en) * 1955-01-19 1956-03-06 Schering Corp 1-hydroxycortisone, 1-hydroxyhydrocortisone and esters thereof
US2968655A (en) * 1956-11-23 1961-01-17 Upjohn Co 11-oxygenated-6-methyl progesterone and intermediates therefor
US2920999A (en) 1957-06-07 1960-01-12 Pfizer & Co C 21-nitrogen derivatives of corticosteroids
GB889766A (en) 1958-03-04 1962-02-21 Olin Mathieson Improvements in steroids and the synthesis thereof
DE1165595B (en) 1958-03-04 1964-03-19 Olin Mathieson Process for the preparation of triamcinolone acetonide-21-hemisuccinate and its salts
US3197469A (en) 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3007923A (en) * 1959-01-22 1961-11-07 Lab Francais Chimiotherapie Process for the fluorination of 9beta, 11beta-epoxy and 5alpha, 6alpha-epoxy steroids
GB898295A (en) 1959-03-18 1962-06-06 Upjohn Co Improvements in or relating to steroids and the manufacture thereof
US3033874A (en) 1960-05-11 1962-05-08 Pfizer & Co C 17beta-propenoyl steroids and process for preparing same
US3033873A (en) 1960-05-11 1962-05-08 Pfizer & Co C 21-aminomethyl-pregnenes
US3020275A (en) 1960-06-07 1962-02-06 American Cyanamid Co 21-nitrogen substituted steroids of the pregnane series and methods of preparing the same
DE1169444B (en) * 1961-02-22 1964-05-06 Schering Ag Process for the preparation of ?-16ª‡-methyl steroids
US3047468A (en) * 1961-06-06 1962-07-31 American Cyanamid Co Method of preparing delta1, 4-3-keto steroids of the pregnane series
US3383394A (en) * 1965-08-30 1968-05-14 Schering Corp Novel 17-acylating process and products thereof
US3798216A (en) 1969-03-07 1974-03-19 Fabrication Des Antibiotique S 9-fluoro-11beta,21-dihydroxy-16alpha,17-(2-propenylidenedioxy)-pregna-1,4-diene-3,20-dione and derivatives thereof
DE2047105C3 (en) 1970-09-18 1979-02-15 Schering Ag, 1000 Berlin Und 4619 Bergkamen 17-chloro steroids and process for their preparation
IT1057859B (en) 1972-04-28 1982-03-30 Sigma Tao Ind Farmaceutiche Sp Triamcinolone derivs - as antiinflammatory agents
SE378110B (en) 1972-05-19 1975-08-18 Bofors Ab
SE378109B (en) 1972-05-19 1975-08-18 Bofors Ab
US4076737A (en) 1975-02-20 1978-02-28 Ciba-Geigy Corporation Aldehydes of the pregnane series and derivatives thereof
IL73337A (en) 1984-10-28 1988-09-30 Yissum Res Dev Co Antitumor steroid-platinum complexes and method for the preparation thereof
ES8605537A1 (en) 1985-07-03 1986-02-01 Elmu Sa Cyclic ketal(s) prodn.
SE8604059D0 (en) 1986-09-25 1986-09-25 Astra Pharma Prod A METHOD OF CONTROLLING THE EPIMERIC DISTRIBUTION IN THE PREPARATION OF 16,17-ACETALS OF PREGNANE DERIVATIVES
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5116829A (en) 1990-04-23 1992-05-26 Kao Corporation Steroid compounds
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
SK87295A3 (en) 1993-01-08 1996-04-03 Astra Ab Novel colon or ileum-specific steroid derivatives
DE4311987A1 (en) 1993-04-07 1994-10-13 Schering Ag New glucocorticoids
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
US5837698A (en) 1996-05-02 1998-11-17 G. D. Searle & Co. Steroid nitrite and nitrate ester derivatives useful as anti-inflammatory drugs
AU3703900A (en) 1999-02-24 2000-09-14 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
SE0101220D0 (en) 2001-04-04 2001-04-04 Astrazeneca Ab New use
US6908934B2 (en) 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
ITMI20020148A1 (en) 2002-01-29 2003-07-29 Nicox Sa NEW CORTICOSTEROIDS
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
US7190468B2 (en) 2002-07-17 2007-03-13 Hewlett-Packard Development Company, L.P. Background document rendering system and method
ES2369542T3 (en) 2002-07-31 2011-12-01 Seattle Genetics, Inc. CONJUGATES OF AURISTATINE AND ITS USE TO TREAT CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE.
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
AU2003265576A1 (en) 2002-08-23 2004-03-11 The Mclean Hospital Corporation Corticosteroid conjugates and uses thereof
PT2277551E (en) 2002-09-06 2013-08-22 Cerulean Pharma Inc Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
CN1414008A (en) 2002-10-17 2003-04-30 南开大学 Steroid compound containing nitrogen and its preparation method
US7015349B2 (en) 2003-03-26 2006-03-21 The Gillette Company Reduction of hair growth
ES2697327T3 (en) 2003-11-06 2019-01-23 Seattle Genetics Inc Intermediate compound for the preparation of conjugates comprising auristatin derivatives and a linker
WO2005063777A1 (en) 2003-12-23 2005-07-14 Corus Pharma Benzylphosphate and substituted benzylphosphate prodrugs for the treatment of pulmonary inflammation
US20050192257A1 (en) 2004-02-26 2005-09-01 Peyman Gholam A. Predictors for patients at risk for glaucoma from steroid therapy
AR048098A1 (en) 2004-03-15 2006-03-29 Wyeth Corp CALIQUEAMYCIN CONJUGATES
MXPA06014065A (en) 2004-06-01 2007-01-31 Genentech Inc Antibody drug conjugates and methods.
EP1602931A1 (en) 2004-06-03 2005-12-07 Universiteit Leiden SR-A antagonists
US7541330B2 (en) 2004-06-15 2009-06-02 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
ATE411053T1 (en) 2004-08-09 2008-10-15 Deutsches Krebsforsch ALBUMINE CONJUGATES CONTAINING A GLUCURON LINK
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
EP1817341A2 (en) 2004-11-29 2007-08-15 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
WO2006135371A1 (en) 2005-06-09 2006-12-21 Kosan Biosciences Incorporated Conjugates with reduced adverse systemic effects
AU2006259604A1 (en) 2005-06-14 2006-12-28 Gilead Sciences, Inc. Substituted phenylphosphates as mutual prodrugs of steroids and beta -agonists for the treatment of pulmonary inflammation and bronchoconstriction
CA2622640A1 (en) 2005-11-02 2007-05-18 Sicor Inc. Improved process for the preparation of ciclesonide
DK1977252T3 (en) 2005-12-22 2013-03-04 Health Prot Agency Improved monocyte activation test with better ability to detect pyrogenic non-endotoxin contaminants in medical products
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
CA2677442A1 (en) 2007-02-05 2008-08-14 Nicox S.A. Nitric oxide releasing steroids
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
AU2008262489B2 (en) 2007-05-23 2013-11-28 Ventana Medical Systems, Inc. Polymeric carriers for immunohistochemistry and in situ hybridization
EP3569251A1 (en) 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
WO2009001364A2 (en) 2007-06-28 2008-12-31 Capsutech Ltd Targeting conjugates comprising active agents encapsulated in cyclodextrin-containing polymers
CN101397328A (en) 2007-09-27 2009-04-01 天津药业研究院有限公司 Nitric oxide-releasing glucocorticosteroid
HUE055815T2 (en) 2007-10-05 2021-12-28 Univ Wayne State Dendrimers for sustained release of compounds
WO2009085880A2 (en) 2007-12-21 2009-07-09 Schering Corporation C-21 thioethers as glucocorticoid receptor agonists
CL2008003803A1 (en) 2007-12-21 2010-02-19 Schering Corp Substituted c20-21 steroid derived compounds, glucocorticoid receptor agonists; pharmaceutical composition comprising said compound; and use to treat or prevent an immune, autoimmune, or inflammatory disease or condition, such as inflammatory colitis and rheumatoid arthritis.
SG189817A1 (en) 2008-04-30 2013-05-31 Immunogen Inc Potent conjugates and hydrophilic linkers
WO2009152171A1 (en) 2008-06-10 2009-12-17 Gilead Sciences, Inc. Corticosteroid linked beta-agonist compounds for use in therapy
JP5622117B2 (en) 2008-07-21 2014-11-12 ポリテリクスリミテッド Novel reagents and methods for conjugating biomolecules
EP2313436B1 (en) 2008-07-22 2014-11-26 Ablynx N.V. Amino acid sequences directed against multitarget scavenger receptors and polypeptides
ES2471145T3 (en) 2009-03-09 2014-06-25 Mikasa Seiyaku Co,. Ltd. Steroid compound
WO2010126953A1 (en) 2009-04-29 2010-11-04 Gilead Sciences, Inc. Corticosteroid linked beta-agonist compounds for use in therapy
WO2010132743A1 (en) 2009-05-15 2010-11-18 Gilead Sciences, Inc. Corticosteroid beta-agonist compounds for use in therapy
CA2770620A1 (en) 2009-08-10 2011-02-17 Mark Smith Thiol protecting group
WO2011020107A2 (en) 2009-08-14 2011-02-17 Georgetown University Compositions and methods for detection and treatment of breast cancer
GB0917044D0 (en) 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
GB0917054D0 (en) * 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
US9375473B2 (en) 2010-02-19 2016-06-28 Cornell Research Foundation, Inc. Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
US20130028917A1 (en) 2010-04-15 2013-01-31 Spirogen Developments Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2012005982A2 (en) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Reporter for rna polymerase ii termination
SG10201912639SA (en) 2010-08-02 2020-02-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
CA2809487C (en) 2010-09-01 2019-02-26 Bayer Cropscience Ag N-(tetrazol-5-yl)- and n-(triazol-5-yl)arylcarboxamides and use thereof as herbicides
US9238690B2 (en) 2010-10-29 2016-01-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
US20120302505A1 (en) 2011-04-21 2012-11-29 Fetzer Oliver S Cyclodextrin-based polymers for therapeutic delivery
SG195183A1 (en) 2011-05-27 2013-12-30 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CA2850375C (en) 2011-10-14 2019-07-02 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
ES2687246T3 (en) 2011-10-14 2018-10-24 Seattle Genetics, Inc. Pyrrolobenzodiazepines and directed conjugates
CA2850096C (en) 2011-10-14 2018-07-03 Spirogen Sarl Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
CN103998450B (en) 2011-10-14 2017-03-08 麦迪穆有限责任公司 Pyrrolobenzodiazepines are tall and erect
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
WO2013085925A1 (en) 2011-12-05 2013-06-13 Igenica, Inc. Antibody-drug conjugates and related compounds, compositions, and methods
GB201122325D0 (en) 2011-12-23 2012-02-01 Cytoguide As Novel formulations
JP2015521602A (en) 2012-06-14 2015-07-30 アンブルックス, インコーポレイテッドAmbrx, Inc. Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
CN104755104A (en) 2012-10-11 2015-07-01 阿森迪斯药物股份有限公司 Diagnosis, prevention and treatment of diseases of the joint
EA201590622A1 (en) 2012-10-16 2015-10-30 Эндосайт, Инк. CONJUGATES FOR DELIVERY OF MEDICINES CONTAINING NOT MEETING IN THE NATURE OF AMINO ACID AND METHODS OF APPLICATION
LT3912642T (en) 2012-10-23 2023-07-25 Synaffix B.V. Modified antibody, antibody-conjugate and process for the preparation thereof
WO2014065575A1 (en) 2012-10-25 2014-05-01 주식회사유한양행 4,5-dihydro-1h-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same
RU2018129572A (en) 2012-12-24 2018-10-12 Эббви Инк. PROTEINS CONNECTING THE PROLACTIN RECEPTOR AND THEIR APPLICATION
KR102401525B1 (en) 2013-03-13 2022-05-24 씨젠 인크. Cyclodextrin and antibody-drug conjugate formulations
EP2988786A4 (en) 2013-04-22 2016-12-21 Avelas Biosciences Inc Selective drug delivery compositions and methods of use
WO2014197854A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
AU2014283185B2 (en) 2013-06-21 2019-05-02 Innate Pharma Enzymatic conjugation of polypeptides
WO2015005459A1 (en) 2013-07-10 2015-01-15 生化学工業株式会社 Pharmaceutical composition for respiratory administration
TWI641620B (en) 2013-08-21 2018-11-21 再生元醫藥公司 Anti-prlr antibodies and uses thereof
SG10201806917PA (en) 2013-10-15 2018-09-27 Seattle Genetics Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
GB201320091D0 (en) 2013-11-14 2014-01-01 Univ Manchester Selective glucocorticoid receptor ligands
CN103694375B (en) 2013-12-13 2016-10-05 北京大学 A kind of triterpene-cyclodextcovalent covalent compound and its production and use
JP6527171B2 (en) 2014-01-24 2019-06-05 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック Orally ingestible compounds for the treatment of E. coli-induced inflammatory bowel disease such as Crohn's disease, processes for preparing them and their use as antiadhesive agents
WO2015153401A1 (en) 2014-04-04 2015-10-08 Merck Sharp & Dohme Corp Phosphate based linkers for intracellular delivery of drug conjugates
IL311108A (en) 2014-04-10 2024-04-01 Daiichi Sankyo Co Ltd Method for producing an anti-her3 antibody-drug conjugate
EP3166638A1 (en) 2014-06-13 2017-05-17 Glykos Finland Oy Payload-polymer-protein conjugates
MX2017007055A (en) 2014-12-03 2017-11-08 Genentech Inc Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof.
CN107249642A (en) 2014-12-03 2017-10-13 豪夫迈·罗氏有限公司 Anti-Staphylococcus aureus antibody rifamycin conjugate and application thereof
JP2018508463A (en) 2014-12-09 2018-03-29 アッヴィ・インコーポレイテッド Bcl-xL inhibitory compound having low cell permeability and antibody drug conjugate comprising the same
WO2016094517A1 (en) 2014-12-09 2016-06-16 Abbvie Inc. Bcl-xl inhibitory compounds and antibody drug conjugates including the same
WO2016120891A1 (en) 2015-01-30 2016-08-04 Coral Drugs Pvt. Ltd. Novel process for preparation of glucocorticoid steroids
CN107635405A (en) 2015-02-06 2018-01-26 索伦托医疗有限公司 Antibody drug conjugate
WO2017006279A1 (en) 2015-07-08 2017-01-12 Aten Porus Lifesciences Cyclodextrin-polymer complexes and compostions and methods of making and using the same
EP3346997A4 (en) 2015-09-10 2019-05-15 Shasqi, Inc. Bioorthogonal compositions
US11510993B2 (en) 2015-10-06 2022-11-29 Merck Sharp & Dohme Llc Antibody drug conjugate for anti-inflammatory applications
US10869929B2 (en) 2016-01-29 2020-12-22 Merck Sharp & Dohme Corp. Phosphonate linkers and their use to facilitate cellular retention of compounds
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
SG11201807827VA (en) 2016-03-25 2018-10-30 Seattle Genetics Inc Process for the preparation of pegylated drug-linkers and intermediates thereof
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
RU2745748C2 (en) 2016-06-02 2021-03-31 Эббви Инк. Agonist of the glucocorticoid receptor and its immunoconjugates
CN109562168A (en) 2016-06-08 2019-04-02 艾伯维公司 Anti-CD 98 antibody and antibody drug conjugates
WO2018058001A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
JP7330101B2 (en) 2016-11-08 2023-08-21 レゲネロン ファーマシューティカルス，インコーポレーテッド Steroids and their protein conjugates
TWI781145B (en) 2017-02-28 2022-10-21 美商伊繆諾金公司 Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
JP2020520926A (en) 2017-05-18 2020-07-16 レゲネロン ファーマシューティカルス，インコーポレーテッド Bis-octahydrophenanthrene carboxamide and protein conjugate thereof
EP3624894A1 (en) 2017-05-18 2020-03-25 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
WO2018218004A1 (en) 2017-05-24 2018-11-29 The Board Of Regents Of The University Of Texas System Linkers for antibody drug conjugates
WO2019034177A1 (en) 2017-08-18 2019-02-21 四川百利药业有限责任公司 Antibody drug conjugate having two different drugs
WO2019034176A1 (en) 2017-08-18 2019-02-21 四川百利药业有限责任公司 Camptothecin-antibody conjugate
KR20200085807A (en) 2017-11-07 2020-07-15 리제너론 파마슈티칼스 인코포레이티드 Hydrophilic linker for antibody drug conjugates
JP7366028B2 (en) 2018-01-08 2023-10-20 レゲネロン ファーマシューティカルス，インコーポレーテッド Steroids and their antibody conjugates
JP7430643B2 (en) 2018-04-06 2024-02-13 シージェン インコーポレイテッド Camptothecin peptide conjugate
JP2021523147A (en) 2018-05-09 2021-09-02 レゲネロン ファーマシューティカルス，インコーポレーテッド Anti-MSR1 antibody and how to use it
SG11202106658XA (en) 2018-12-21 2021-07-29 Regeneron Pharma Rifamycin analogs and antibody-drug conjugates thereof
EP3908323A2 (en) 2019-01-08 2021-11-17 Regeneron Pharmaceuticals, Inc. Traceless linkers and protein-conjugates thereof

Also Published As

Publication number Publication date
ZA201902871B (en) 2023-12-20
AU2017359043B2 (en) 2022-06-16
JP2023153988A (en) 2023-10-18
JP2019536765A (en) 2019-12-19
MX2019005330A (en) 2019-09-11
KR20190074310A (en) 2019-06-27
WO2018089373A9 (en) 2018-07-12
US20180155389A1 (en) 2018-06-07
US20240101594A1 (en) 2024-03-28
JP7330101B2 (en) 2023-08-21
US20210332080A1 (en) 2021-10-28
EP3538539A2 (en) 2019-09-18
BR112019009019A2 (en) 2019-07-09
US10711032B2 (en) 2020-07-14
CN115651056A (en) 2023-01-31
IL266353B1 (en) 2023-11-01
CO2019005966A2 (en) 2019-07-10
CA3042428A1 (en) 2018-05-17
CL2019001259A1 (en) 2019-07-19
IL266353A (en) 2019-06-30
US11760775B2 (en) 2023-09-19
CN110291097A (en) 2019-09-27
WO2018089373A3 (en) 2018-06-21
US20210040144A1 (en) 2021-02-11
AU2017359043A1 (en) 2019-05-23
IL307357A (en) 2023-11-01
PH12019501021A1 (en) 2019-06-24
KR20240025695A (en) 2024-02-27
WO2018089373A2 (en) 2018-05-17
IL266353B2 (en) 2024-03-01
MX2021012927A (en) 2022-01-31

Similar Documents

Publication Publication Date Title
IL266353A (en) Steroids and protein-conjugates thereof
HK1251426A1 (en) Dispenser assembly and related methods
IL264813B (en) 2-oxo-imidazopyridines and their use
IL261140A (en) Anti-tnfalpha-antibodies and functional fragments thereof
IL249230A0 (en) Combination comprising a glucocorticoid and edo-s101
SG10201508941SA (en) Intermodal devices and methods
IL261031A (en) Anti-tnfalpha-antibodies and functional fragments thereof
GB201612858D0 (en) New uses and methods
IL261261A (en) Anti-tnfalpha-antibodies and functional fragments thereof
PL3565374T3 (en) Region configuration methods and devices
IL261098A (en) Anti-tnfalpha-antibodies and functional fragments thereof
GB2548839B (en) New uses and methods
HK1247122A1 (en) Combinations and uses thereof
GB201603311D0 (en) New uses and methods
IL254241A0 (en) Etv2 and uses thereof
GB2563869B (en) Materials and methods
IL261793A (en) Anti-tnfalpha-antibodies and functional fragments thereof
GB201517786D0 (en) Methods and materials
GB2560211B (en) Methods and devices
IL275211A (en) Fast and partition-resilient blockchains
GB201513590D0 (en) Devices and methods
GB201508028D0 (en) Sandfalls and the like
GB201707279D0 (en) Multiearphones and polyearphones
GB2545167B (en) Cloches and use thereof
GB201513796D0 (en) Materials and Devices